AFFITOPE AD01 + aluminum hydroxide

**AFFITOPE AD01 + aluminum hydroxide** is a combination therapeutic vaccine consisting of AFFITOPE AD01, a synthetic peptide designed as a mimotope of the N-terminus of beta-amyloid (Aβ), and aluminum hydroxide as an adjuvant. AFFITOPE AD01 aims to induce an immune response against beta-amyloid by generating antibodies that target the amyloid precursor protein (APP) and Aβ aggregates, with the intent to decrease amyloid plaque deposition and modify disease progression in Alzheimer's disease. The vaccine formulation is intended to minimize the activation of autoreactive T-cells and avoid undesired cross-reactivity, thereby promoting safety and tolerability. Aluminum hydroxide serves as an immunostimulant adjuvant to enhance antibody response[1][3][2]. The developer and sponsor of AFFITOPE AD01 clinical studies is AFFiRiS AG[1][5].

Other names

AFFITOPE AD01AD-1AD1AD 1